



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/661,088 |
| Sheet | 1 | of | 13 | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| | | | | Attorney Docket Number | 16051-9US CC |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Document Number Number – Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| BP | | US-5,563,050 | | | |
| | | US-6,506,559 | | | |
| | | US-5,023,252 | | | |
| | | US-5,580,859 | | | |
| | | US-4,806,463 | | | |
| | | US-5,248,670 | | | |
| | | US-5,591,720 | | | |
| | | US-5,952,490 | | | |
| | | US-5,998,602 | | | |
| | | US-6,184,369 | | | |
| | | US-5,264,423 | | | |
| | | US-5,276,019 | | | |
| | | US-6,316,190 | | | |
| | | US-5,218,103 | | | |
| | | US-5,684,148 | | | |
| | | US-5,452,496 | | | |
| | | US-5,278,302 | | | |
| | | US-5,750,666 | | | |
| ↓ | | US-5,602,244 | | | |
| | | US-5,508,270 | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant Of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| BP | | WO 03/02903 | . | | |
| | | WO 99/32619 | | | |
| | | WO 01/75164 | | | |
| | | WO 92/03051 | | | |
| | | WO 94/17093 | | | |
| | | WO 94/02499 | | | |
| ↓ | | WO 94/26764 | | | |
| | | WO 97/13499 | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 2 | of | 13 | Attorney Docket Number | 16051-9US CC |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| | | Number – Kind Code ² (if known) | | | |
| BP | | US-4,469,863 | | | |
| | | US-5,610,289 | | | |
| | | US-5,256,775 | | | |
| | | US-5,366,878 | | | |
| | | US-5,476,925 | | | |
| | | US-5,023,243 | | | |
| | | US-5,130,302 | | | |
| | | US-5,177,198 | | | |
| | | US-5,378,825 | | | |
| | | US-5,386,023 | | | |
| | | US-5,489,677 | | | |
| | | US-5,264,562 | | | |
| | | US-5,264,564 | | | |
| | | US-5,223,618 | | | |
| | | US-5,770,713 | | | |
| | | US-5,543,152 | | | |
| | | US-4,426,330 | | | |
| | | US-4,534,899 | | | |
| ↓ | | US-5,705,188 | | | |
| | | US-5,013,556 | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant Of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| | | Country Code 3 – Number 4 – Kind Code 5 (if known) | | | |
| BP | | WO 90/04384 | | | |
| | | WO 97/30731 | | | |
| | | EP 0 496 813 B1 | | | |
| | | EP 0 445 131 B1 | | | |
| | | WO 91/05545 | | | |
| | | WO 94/20073 | | | |
| ↓ | | WO 96/10391 | | | |
| | | WO 98/39352 | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 3 | of | 13 | Attorney Docket Number | 16051-9US CC |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Document Number Number – Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| BP | | US-5,356,633 | | | |
| | | US-5,213,804 | | | |
| | | US-5,225,212 | | | |
| | | US-5,540,935 | | | |
| | | US-5,556,948 | | | |
| | | US-6,316,190 | | | |
| | | US-5,264,221 | | | |
| | | US-5,665,710 | | | |
| | | US-4,806,463 | | | |
| | | US-5,248,670 | | | |
| | | US-5,695,979 | | | |
| | | US-5,591,623 | | | |
| | | US-5,514,788 | | | |
| | | US-5,652,355 | | | |
| | | US-6,143,881 | | | |
| | | US-6,346,614 | | | |
| | | US-5,591,721 | | | |
| | | US-6,608,035 | | | |
| ↓ | | US-3,687,808 | | | |
| | | US-5,625,050 | | | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant Of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| BP | | WO 99/14226 | | | |
| | | WO 96/40062 | | | |
| | | WO 97/04787 | | | |
| | | WO 04/02419 | | | |
| ↓ | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/661,088 |
| | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 4 | of | 13 | Attorney Docket Number | 16051-9US CC |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| | | | |
|-----------------------|-----------|--------------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|-----------------------|-----------|--------------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 5 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | T ² |
| BP | | ADJOU et al., "A novel generation of heparan sulfate mimetics for the treatment of prion diseases", 2003, <i>J. Gen. Virol.</i> 84:2595-2603. | | | |
| | | AGRAWAL, "Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides", 1999, <i>Biochim. Biophys. Acta</i> 1489:53-68. | | | |
| | | AGRAWAL and KANDIMALLA, "Antisense therapeutics: is it as simple as complementary base recognition?", 2000, <i>Mol. Med. Today</i> 6:72-81. | | | |
| | | AKHTAR et al., "The delivery of antisense therapeutics", 2000, <i>Advanced Drug Delivery Reviews</i> 44:3-21. | | | |
| | | ALLAKHVERDI et al., "Inhibition of Antigen-induced Eosinophilia and Airway Hyperresponsiveness by Antisense Oligonucleotides Directed against the Common β Chain of IL-3, IL-5, GM-CSF Receptors in a Rat Model of Allergic Asthma", 2002, <i>Am. J. Respir. Crit. Care Med.</i> 165:1015-1021. | | | |
| | | ANDREOLA et al., "DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity", 2001, <i>Biochemistry</i> , 40:10087-10094. | | | |
| | | BAKER et al., "2-O-(2-Methoxy)ethyl-modified Anti-intercellular Adhesion Molecule 1 (ICAM-1) Oligonucleotides Selectively Increase the ICAM-1 mRNA Level and Inhibit Formation of the ICAM-1 Translation Initiation Complex in Human Umbilical Vein Endothelial Cells", 1997, <i>J. Biol. Chem.</i> 272 (18):11994-12000. | | | |
| | | BALL et al., "Clinical Potential of Respirable Antisense Oligonucleotides (RASONs) in Asthma", 2003, <i>Am. J. Pharmacogenomics</i> 3 (2):97-106. | | | |
| | | BANKS et al., "Delivery across the Blood-Brain Barrier of Antisense Directed against Amyloid β : Reversal of Learning and Memory Deficits in Mice Overexpressing Amyloid Precursor Protein", 2001, <i>J. Pharmacol. Exp. Ther.</i> 297 (3):1113-1121. | | | |
| ▼ | | BARDOS et al., "Structure-Activity Relationships and Mode of Action of 5-Mercapto-Substituted Oligo- and Polynucleotides as Antitemplates Inhibiting Replication of Human Immunodeficiency Virus Type 1", 1992, <i>Antimicrob. Agents and Chemother.</i> 36 (1):108-114. | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP-609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> | | | | Application Number | 10/661,088 |
| | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 6 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---------------------------------|-----------------------|--|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | | T ² |
| BP | | BARRET et al., "Evaluation of Quinacrine Treatment for Prion Diseases", 2003, <i>J. of Virol.</i> 77 (15):8462-8469. | | | | |
| | | BATE et al., "Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity", 2004, <i>J. of Biol. Chem.</i> 279 (15):14983-14990. | | | | |
| | | BOUSSIF et al., "A versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in vivo: Polyethylenimine", 1995, <i>Proc. Natl. Acad. Sci. USA.</i> 92 (16):7297-7301. | | | | |
| | | BRIGGER et al., "Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting", 2002, <i>J. Pharmacol. Exp. Ther.</i> 303 (3):928-936. | | | | |
| | | CASPER, "Discovery of a Novel Target for Potential Cancer Therapy", Joint Bayer Science Forum – ACS November 24 th Dinner Meeting. 2003, The FILTERPAPER, Andy Edelbrock Bayer Corporation, page 3 (abstract). | | | | |
| | | CAUGHEY et al., "Sulfated Polyanion Inhibition of Scrapie-Associated PrP Accumulation in Cultured Cells", 1993, <i>J. Virol.</i> 67 (2):643-650. | | | | |
| | | CHEN et al., "Antisense Oligonucleotides Demonstrate a Dominant Role of c-Ki-RAS Proteins in Regulating the Proliferation of Diploid Human Fibroblasts", 1996, <i>J. Biol. Chem.</i> 271 (45):28259-28265. | | | | |
| | | CHEONG et al., "Structure of influenza virus panhandle RNA studied by NMR spectroscopy and molecular modeling", 1999, <i>Nuc. Acids. Res.</i> 27 (5): 1392-1397. | | | | |
| | | CHIANG et al., "Antisense Oligonucleotides Inhibit Intercellular Adhesion Molecule 1 Expression by Two Distinct Mechanisms", 1991, <i>J. Biol. Chem.</i> 266 (27):18162-18171. | | | | |
| ▼ | | CIOFFI et al., "Selective Inhibition of A-Raf and C-Raf mRNA Expression by Antisense Oligodeoxynucleotides in Rat Vascular Smooth Muscle Cells: Role of A-Raf and C-Raf in Serum-Induced Proliferation", 1997, <i>Mol. Pharmacol.</i> 51:383-389. | | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 7 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---------------------------------|-----------------------|---|--|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | | T ² |
| BP | | CROOKE et al., "In Vitro Toxicological Evaluation of ISIS 1082, a Phosphorothioate Oligonucleotide Inhibitor of Herpes Simplex Virus", 1992, <i>Antimicrob. Agents Chemother.</i> 36 (3):527-532. | | | | |
| | | DASS, "Vehicles for oligonucleotide delivery to tumours", 2002, <i>Journal of Pharmacy and Pharmacology</i> 54:3-27. | | | | |
| | | DASS, "Liposome-Mediated Delivery of Oligodeoxynucleotides In Vivo", 2002, <i>Drug Delivery</i> , 9:169-180. | | | | |
| | | DHEUR et al., "Polyethylenimine but Not Cationic Lipid Improves Antisense Activity of 3'-Capped Phosphodiester Oligonucleotides", 1999, <i>Antisense & Nucleic Acid Drug Development</i> , 9:515-525. | | | | |
| | | DOH-URA et al., "Treatment of Transmissible Spongiform Encephalopathy by Intraventricular Drug Infusion in Animal Models", 2004, <i>J. Virol.</i> 78 (10):4999-5006. | | | | |
| | | ELBASHIR et al., "RNA interference is mediated by 21- and 22-nucleotide RNAs", 2001, <i>Genes & Development</i> 15:188-200. | | | | |
| | | ELBASHIR et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", 2001, <i>Nature</i> 411:494-498. | | | | |
| | | FINOTTO et al., "Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma", 2001, <i>J. Allergy Clin. Immunol.</i> 107 (2) :279-286. | | | | |
| | | FISSET et al., "Modulation of allergic response in nasal mucosa by antisense oligodeoxynucleotides for IL-4", 2003, <i>J. Allergy Clin. Immunol.</i> 111 (3) :580-586. | | | | |
| ▼ | | GARRETT et al., "In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye", 2001, <i>J. Gene Med.</i> 3:373-383. | | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|---|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 8 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | T ² |
| BP | | GORLACH et al., "Antisense repression in <i>Cryptococcus neoformans</i> as a laboratory tool and potential antifungal strategy", 2002, <i>Microbiology</i> 148:213-219. | | |
| | | GRIGORIEV et al., "Effects of the polyene antibiotic derivative MS-8209 on the astrocyte lysosomal system of scrapie-infected hamsters", 2002, <i>J. Mol. Neurosci.</i> 18:271-281. | | |
| | | HARBOTH et al., "Identification of essential genes in cultured mammalian cells using small interfering RNAs", 2001, <i>Journal of Cell Science</i> 114 (24) 4557-4565. | | |
| | | HORVATH et al., "Potent inhibition of HIV-1 entry by (s ⁴ dU) ₃₅ ", 2005, <i>Virology</i> 334:214-223. | | |
| | | HUGHES et al., "The cellular delivery of antisense oligonucleotides and ribozymes", 2001, <i>Drug Discovery Today</i> . 6 (6) :303-315. | | |
| | | HUWYLER et al., "Brain drug delivery of small molecules using immunoliposomes", 1996, <i>Proc. Natl. Acad. Sci. USA</i> 93:14164-14169. | | |
| | | INOUE et al., "Synthesis and properties of novel nucleic acid probes", 1985, <i>Symposium Series - Nucleic Acids Research</i> No. 16:165-168. | | |
| | | INOUE et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H", 1987, <i>FEBS Letters</i> 215 (2) :327-330. | | |
| | | JAASKELAINEN et al., "A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides", 2000, <i>European Journal of Pharmaceutical Sciences</i> 10:187-193. | | |
| | | KANAGARATNAM et al., "Malaria merozoite surface protein antisense oligodeoxynucleotides lack antisense activity but function as polyanions to inhibit red cell invasion", 1998, <i>Int. J. Biochem. Cell Biol.</i> 30:979-985. | | |
| ▼ | | KOCISKO et al., "New Inhibitors of Scrapie-Associated Prion Protein Formation in a Library of 2,000 Drugs and Natural Products", 2003, <i>J. Virol.</i> 77 (19) :10288-10294. | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

9 of 13

Complete if Known

| | |
|----------------------|------------------------|
| Application Number | 10/661,088 |
| Filing Date | September 12, 2003 |
| First Named Inventor | Andrew Vaillant et al. |
| Art Unit | 1648 |
| Examiner Name | Bo PENG |

Attorney Docket Number 16051-9US CC

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| BP | | KOSTER et al., "Emerging therapeutic agents for transmissible spongiform encephalopathies: a review", 2003, J. Vet Pharmacol. Ther. 26:315-26. | |
| | | KURRECK, "Antisense technologies. Improvement through novel chemical modifications", 2003, Eur. J. Biochem. 270:1628-1644. | |
| | | KUWASAKI et al., "Inhibition of human immunodeficiency virus 1 replication <i>in vitro</i> by a self-stabilized oligonucleotide with 2'-O-methyl-guanosine-uridine quadruplex motifs", 2003, J. Antimicrob. Chemother. 51:813-819. | |
| | | LAU et al., "Abrogation of c-Raf expression induces apoptosis in tumor cells", 1998, Oncogene 16:1899-1902. | |
| | | LEUNG and SHAH, in: <i>Controlled Release of drugs: Polymers and aggregate systems</i> , Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215. | |
| | | LUO et al., "Inhibition of influenza viral polymerases by minimal viral RNA decoys", 1997, J. Gen. Virol. 78: 2329-2333. | |
| | | de MERGNY et al., "Kinetics and thermodynamics of i-DNA formation: phosphodiester versus modified oligodeoxynucleotides", 1998, Nucleic Acids Res. 26 (21): 4797-4803. | |
| | | de MONBRISON et al., "Introducing antisense oligonucleotides into <i>Pneumocystis carinii</i> ", 2002, J. Microbiol. Methods 50:211-213. | |
| | | MONIA et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression", 1993, J. Biol. Chem. 268 (19) :14514-14522. | |
| ↓ | | MORASSUTTI et al., "Effect of phosphorothioate modifications on the ability of GTn oligodeoxynucleotides to specifically recognize single-stranded DNA-binding proteins and to affect human cancer cellular growth" 1999, Biochimie 81:1115-1122. | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|----|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 10 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | T ² |
| BP | | MOU and GRAY, "The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications", 2002, <i>Nucleic Acids Res.</i> 30 (3) :749-758. | | |
| | | NAKAJIMA et al., "Results of Quinacrine Administration to Patients with Creutzfeldt-Jakob Disease", 2004, <i>Dement. Geriatr. Cogn. Disord.</i> 17:158-163. | | |
| | | NOGUCHI et al., "Remarkable induction of apoptosis in cancer cells by a novel cationic liposome complexed with a bcl-2 antisense oligonucleotide", 2003, <i>Journal of Controlled Release</i> 88:313-320. | | |
| | | NOONPAKDEE et al., "Inhibition of <i>Plasmodium falciparum</i> proliferation in vitro by antisense oligodeoxynucleotides against malarial topoisomerase II", 2003, <i>Biochem. and Biophys. Res. Commun.</i> 302:659-664. | | |
| | | O'BRIEN et al., "Antisense BCR-ABL Oligomers Cause Non-Specific Inhibition of Chronic Myeloid Leukemia Cell Lines", 1994, <i>Leukemia</i> 8 (12) :2156-2162. | | |
| | | OMORI et al., "Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin", 2003, <i>Neurol. Res.</i> 25:275-279. | | |
| | | Orum et al., "Locked nucleic acids: A promising molecular family for gene-function analysis and antisense drug development", 2001, <i>Current Opinion in Molecular Therapeutics</i> 3 (3):239-243. | | |
| | | PAN et al., "Isolation of virus-neutralizing RNAs from a large pool of random sequences", 1995, <i>Proc. Natl. Acad. Sci. USA</i> 92:11509-11513. | | |
| | | PAPUCCI et al., "Phosphodiester Oligonucleotides Inhibit Mitosis and Trigger Apoptosis by a Non-Antisense, p53-Mediated Mechanism", 2002, <i>Antisense & Nucleic Acid Drug Development</i> 12:21-31. | | |
| | | PEREZ et al., "Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides", 1994, <i>Proc. Natl. Acad. Sci. USA</i> 91:5957-5961. | | |
| ↓ | | POLI et al., "In vitro Evaluation of the Anti-prionic Activity of Newly Synthesized Congo Red Derivatives", 2003, <i>Arzneim.-Forsch./Drug Res.</i> 53 (12):875-888. | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|----|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 11 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------|--|--|--|--|
| Examiner Initials* | Cite No.* | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | |
| BP | | PRIOLA et al., "Porphyrin and Phthalocyanine Antiscrapie Compounds", 2000, <i>Science</i> 287: 1503-1506. | | | |
| | | PROSKE et al., "Prion-Protein-Specific Aptamer Reduces PrP ^{Sc} Formation", 2002, <i>Chemical Biol. Chem.</i> 3:717-725. | | | |
| | | RAMAZEILLES et al., "Antisense phosphorothioate oligonucleotides: Selective killing of the intracellular parasite <i>Leishmania amazonensis</i> ", 1994, <i>Proc. Natl. Acad. Sci. USA</i> 91:7859-7863. | | | |
| | | RHIE et al., "Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion", 2003, <i>J. Biol. Chem.</i> , 278 (41):39697-39705. | | | |
| | | Rieger, in: <i>Pharmaceutical Dosage Forms</i> , Lieberman, Rieger and Banker (Eds), 1988, Marcel Dekker, INC., New York, NY, Vol. 1, pp. 285-366 | | | |
| | | ROH et al., "Down-Regulation of HER2/neu Expression Induces Apoptosis in Human Cancer Cells That Overexpress HER2/neu", 2000, <i>Cancer Research</i> 60:560-565. | | | |
| | | ROSOFF, in: <i>Pharmaceutical Dosage Forms</i> , Lieberman, Rieger and Banker (Eds), 1988, Marcel Dekker, INC., New York, NY, Vol. 1, pp.245-282. | | | |
| | | SCHMIDT et al., "Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis", 2003, <i>Brain</i> 126 :1895-1904. | | | |
| | | SHYNG et al., "Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrP ^C , in Cultured Cells", 1995, <i>J. Biol. Chem.</i> 270 (50) :30221-30229. | | | |
| ▼ | | SIERAKOWSKA et al., "Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides", 1996, <i>Proc. Natl. Acad. Sci. USA</i> 93:12840-12844. | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|----|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 12 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | T ² |
| BP | | SMETSERS et al., "An antisense Bcr-Abl phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukaemia patient cells by a non-antisense mechanism", 1997, <i>British Journal of Haematology</i> 96:377-381. | | |
| | | SUPATTAPONE et al., "Branched Polyamines Cure Prion-Infected Neuroblastoma Cells", 2001, <i>J. Virol.</i> 75 (7):3453-3461. | | |
| | | TCHATALBACHEV et al., "The packaging signal of influenza viral RNA molecules", 2001, <i>RNA</i> 7: 979-989. | | |
| | | UHLMANN and PEYMAN, "Antisense Oligonucleotides: A New Therapeutic Principle", 1990, <i>Chemical Reviews</i> 90 (4):544-584. | | |
| | | VAN DEVENTER et al., "A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis", 2004, <i>Gut</i> 53:1646-1651. | | |
| | | VINOGRADOV et al., "Nanogels for Oligonucleotide Delivery to the Brain", 2004, <i>Bioconjug. Chem.</i> 15:50-60. | | |
| | | WANG et al., "Sequence-independent Inhibition of In Vitro Vascular Smooth Muscle Cell Proliferation, Migration, and In Vivo Neointimal Formation by Phosphorothioate Oligodeoxynucleotides", 1996, <i>J. Clin. Invest.</i> 98 (2):443-450. | | |
| | | WHITE et al., "Inhibition of the Multiple Antibiotic Resistance (<i>mar</i>) Operon in <i>Escherichia coli</i> by Antisense DNA Analogs", 1997, <i>Antimicrobial Agents and Chemotherapy</i> 41 (12):2699-2704. | | |
| | | WHITE et al., "Development of novel methods for delivering therapeutic oligonucleotides to the central nervous system", 2003, <i>Society for Neuroscience</i> , Program #325.5, Abstract. | | |
| ▼ | | WHITE et al., "Antisense oligonucleotide treatments for psoriasis", 2004, <i>Expert. Opin. Biol. Ther.</i> 4(1):75-81. | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|--|----|----|----|------------------------|------------------------|
| Substitute for form 1449PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | Application Number | 10/661,088 |
| (use as many sheets as necessary) | | | | Filing Date | September 12, 2003 |
| | | | | First Named Inventor | Andrew Vaillant et al. |
| | | | | Art Unit | 1648 |
| | | | | Examiner Name | Bo PENG |
| Sheet | 13 | of | 13 | Attorney Docket Number | 16051-9US CC |

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | T ² |
| BP | | XU et al., "Inhibition of DNA Replication and Induction of S Phase Cell Cycle Arrest by G-rich Oligonucleotides", 2001, <i>The Journal of Biological Chemistry</i> 276 (46):43221-43230. | | | |
| | | YANG et al., "Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing", 2002, <i>Nucl. Acids Res.</i> 30 (23):1-8. | | | |
| | | YU et al., "Hybrid Oligonucleotides: Synthesis, Biophysical Properties, Stability Studies, and Biological Activity", 1996, <i>Bioorganic. Med. Chem.</i> 4 (10):1685-1692. | | | |
| | | YU et al., "Prediction of Clinical Responses in a Simulated Phase III Trial of Crohn's Patients Administered the Antisense Phosphorothioate Oligonucleotide ISIS 2302: Comparison of Proposed Dosing Regimens", 2003, <i>Antisense Nucleic Acid Drug Dev.</i> 13:57-66. | | | |
| | | ZELLWEGER et al., "Antitumor Activity of Antisense Clusterin Oligonucleotides Is Improved in Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry", 2001, <i>J. Pharmacol. and Experimental Therapeutics</i> 298 (3):934-940. | | | |
| | | ZHANG et al., "A Simple Glycol Nucleic Acid", 2005, <i>J. Am. Chem. Soc.</i> 127:4174-4175. | | | |
| | | ZHANG et al., "The Study on Brain Targeting of the Amphotericin B Liposomes", 2003, <i>J. Drug. Target.</i> 11 (2):117-122. | | | |
| | | ZHANG et al., "Global Non-Viral Gene Transfer to the Primate Brain Following Intravenous Administration", 2003, <i>Mol. Ther.</i> 7 (1):11-18. | | | |
| ↓ | | The Concise Encyclopedia of Polymer Science and Engineering, Jacqueline I. Kroschwitz, 1998, ISBN: 0-471-31856-6, 1341 pages, pp. 858-859. | | | |
| | | | | | |

| | | | |
|--------------------|-----------|-----------------|------------|
| Examiner Signature | /Bo Peng/ | Date Considered | 01/17/2007 |
|--------------------|-----------|-----------------|------------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.